{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:47:53Z","timestamp":1767649673996,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health","award":["TC 277\/2013"],"award-info":[{"award-number":["TC 277\/2013"]}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["BPD-00205-13"],"award-info":[{"award-number":["BPD-00205-13"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["167663\/2013-5"],"award-info":[{"award-number":["167663\/2013-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PANLAR Rheumatology Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1854-6","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T13:03:24Z","timestamp":1552568604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis"],"prefix":"10.1186","volume":"21","author":[{"name":"on behalf of the Collaborative Group for Studies of Yellow Fever Vaccine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-3802","authenticated-orcid":false,"given":"Clarissa de Castro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina","family":"Campi-Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u0101es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana Grazziela","family":"Coelho-dos-Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lis Ribeiro do Valle","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Chaves","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael Artur","family":"da Costa-Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina Vanderley","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Lourdes de Sousa","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila Maria Barbosa","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Magda","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edcia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"1854_CR1","doi-asserted-by":"publisher","unstructured":"Araki Y, Mimura T. The mechanisms underlying chronic inflammation in rheumatoid arthritis from the perspective of the epigenetic landscape. J Immunol Res. 2016:6290682. \n                    https:\/\/doi.org\/10.1155\/2016\/6290682\n                    \n                  .","DOI":"10.1155\/2016\/6290682"},{"key":"1854_CR2","first-page":"1166","volume":"29","author":"A Spindler","year":"2002","unstructured":"Spindler A, Bellomio V, Berman A, Lucero E, Baigorria M, Paz S, et al. Prevalence of rheumatoid arthritis in Tucuman. Argentina J Rheumatol. 2002;29:1166\u201370.","journal-title":"Argentina J Rheumatol"},{"key":"1854_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3899\/jrheum.100951","volume":"86","author":"I Pelaez-Ballestas","year":"2011","unstructured":"Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011;86:3\u20138.","journal-title":"J Rheumatol Suppl"},{"key":"1854_CR4","first-page":"169","volume":"33","author":"JF Marques-Neto","year":"1993","unstructured":"Marques-Neto JF, Gon\u00e7alves ET, Langen LFOB, Cunha MFL, Radominski S, Oliveira SM, et al. Multicentric study of the prevalence of adult rheumatoid arthritis in Brazilian population samples. Rev Bras Reumatol. 1993;33:169\u201373.","journal-title":"Rev Bras Reumatol"},{"key":"1854_CR5","first-page":"594","volume":"31","author":"ER Senna","year":"2004","unstructured":"Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM, et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004;31:594\u20137.","journal-title":"J Rheumatol"},{"key":"1854_CR6","unstructured":"Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2017;36:317-28."},{"key":"1854_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.rbr.2014.04.002","volume":"54","author":"LF Muniz","year":"2014","unstructured":"Muniz LF, Silva CR, Costa TF, da Mota LM. Vaccination in patients from Brasilia cohort with early rheumatoid arthritis. Rev Bras Reumatol. 2014;54:349\u201355.","journal-title":"Rev Bras Reumatol"},{"key":"1854_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","volume":"43","author":"MA Friedman","year":"2017","unstructured":"Friedman MA, Winthrop KL. Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist. Rheum Dis Clin N Am. 2017;43:1\u201313.","journal-title":"Rheum Dis Clin N Am"},{"key":"1854_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bjid.2017.02.004","volume":"21","author":"LZ Goldani","year":"2017","unstructured":"Goldani LZ. Yellow fever outbreak in Brazil, 2017. Braz J Infect Dis. 2017;21:123\u20134.","journal-title":"Braz J Infect Dis"},{"key":"1854_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.12688\/f1000research.11280.1","volume":"6","author":"Y Ortiz-Martinez","year":"2017","unstructured":"Ortiz-Martinez Y, Patino-Barbosa AM, Rodriguez-Morales AJ. Yellow fever in the Americas: the growing concern about new epidemics. F1000Res. 2017;6:398.","journal-title":"F1000Res"},{"key":"1854_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Simoes","year":"2012","unstructured":"Simoes M, Camacho LA, Yamamura AM, Miranda EH, Cajaraville AC, Silva-Freire M. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals. 2012;40:399\u2013404.","journal-title":"Biologicals"},{"key":"1854_CR12","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1590\/s1678-9946201759002","volume":"59","author":"KT Miyaji","year":"2017","unstructured":"Miyaji KT, Avelino-Silva VI, Simoes M, Freire MD, Medeiros CR, Braga PE, et al. Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. Rev Inst Med Trop S Paulo. 2017;59:e2 \n                    https:\/\/doi.org\/10.1590\/s1678-9946201759002\n                    \n                  .","journal-title":"Rev Inst Med Trop S Paulo"},{"key":"1854_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","volume":"12","author":"AC Campi-Azevedo","year":"2016","unstructured":"Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12:491\u2013502.","journal-title":"Hum Vaccin Immunother"},{"key":"1854_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jir439","volume":"204","author":"M Luiza-Silva","year":"2011","unstructured":"Luiza-Silva M, Campi-Azevedo AC, Batista MA, Martins MA, Avelar RS, Silveira- Lemos D, et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis. 2011;204:873\u201383.","journal-title":"J Infect Dis"},{"key":"1854_CR15","doi-asserted-by":"publisher","unstructured":"Costa-Pereira C, Campi-Azevedo AC, Coelho-dos-Reis JG, Peruhype-Magalh\u0101es V, Ara\u00fajo MSS, Antonelli LRV, et al. Multi-parameter approach to evaluate the timing of memory status after primary 17DD-YF vaccination. PLoS Negl Trop Dis. 2018. \n                    https:\/\/doi.org\/10.1371\/journal.pntd.0006462\n                    \n                  .","DOI":"10.1371\/journal.pntd.0006462"},{"key":"1854_CR16","doi-asserted-by":"publisher","unstructured":"Watson AM, Klimstra WB. T cell-mediated immunity towards yellow fever virus and useful animal models. Viruses. 2017;9. \n                    https:\/\/doi.org\/10.3390\/v9040077\n                    \n                  .","DOI":"10.3390\/v9040077"},{"key":"1854_CR17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","volume":"25","author":"RA Mason","year":"1973","unstructured":"Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25:539\u201344.","journal-title":"Appl Microbiol"},{"key":"1854_CR18","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","volume":"29","author":"JG Julander","year":"2011","unstructured":"Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011;29:6008\u201316.","journal-title":"Vaccine"},{"key":"1854_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","volume":"38","author":"LA Camacho","year":"2004","unstructured":"Camacho LA, Freire MS, Leal ML, Aguiar SG, Nascimento JP, Iguchi T, et al. Immunogenicity of WHO-17D and brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica. 2004;38:671\u20138.","journal-title":"Rev Saude Publica"},{"key":"1854_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","volume":"4","author":"M Niedrig","year":"1999","unstructured":"Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Tropical Med Int Health. 1999;4:867\u201371.","journal-title":"Tropical Med Int Health"},{"key":"1854_CR21","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","volume":"32","author":"Collaborative Group for Studies on Yellow Fever Vaccines","year":"2014","unstructured":"Collaborative Group for Studies on Yellow Fever Vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014;32:4977\u201384.","journal-title":"Vaccine"},{"key":"1854_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28:710\u201322.","journal-title":"Immunity"},{"key":"1854_CR23","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","volume":"183","author":"RS Akondy","year":"2009","unstructured":"Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183:7919\u201330.","journal-title":"J Immunol"},{"key":"1854_CR24","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.4049\/jimmunol.1202234","volume":"190","author":"K Blom","year":"2013","unstructured":"Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190:2150\u20138.","journal-title":"J Immunol"},{"key":"1854_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2249.2006.03317.x","volume":"148","author":"MA Martins","year":"2007","unstructured":"Martins MA, Silva ML, Marciano AP, Peruhype-Magalhaes V, Eloi-Santos SM, Ribeiro JG, et al. Activation\/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol. 2007;148:90\u2013100.","journal-title":"Clin Exp Immunol"},{"key":"1854_CR26","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1016\/j.vaccine.2009.07.028","volume":"27","author":"PC Neves","year":"2009","unstructured":"Neves PC, Matos DC, Marcovistz R, Galler R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine. 2009;27:5543\u20139.","journal-title":"Vaccine"},{"key":"1854_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.vaccine.2010.08.046","volume":"29","author":"ML Silva","year":"2011","unstructured":"Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine. 2011;29:583\u201392.","journal-title":"Vaccine"},{"key":"1854_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1128\/CVI.00369-09","volume":"17","author":"ML Silva","year":"2010","unstructured":"Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol. 2010;17:118\u201326.","journal-title":"Clin Vaccine Immunol"},{"key":"1854_CR29","doi-asserted-by":"publisher","first-page":"e000484","DOI":"10.1136\/rmdopen-2017-000484.","volume":"3","author":"E Rakoczi","year":"2017","unstructured":"Rakoczi E, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3:e000484. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2017-000484.\n                    \n                   Review.","journal-title":"RMD Open"},{"key":"1854_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309\u201318.","journal-title":"Clin Infect Dis"},{"key":"1854_CR31","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/art.30325","volume":"6","author":"C Gabay","year":"2011","unstructured":"Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;6:1486\u201396.","journal-title":"Arthritis Rheum"},{"key":"1854_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13075-014-0506-0","volume":"16","author":"ZH McMahan","year":"2014","unstructured":"McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther. 2014;16:506.","journal-title":"Arthritis Res Ther"},{"key":"1854_CR33","unstructured":"Sociedade Brasileira de Reumatologia. Nota t\u00e9cnica SBR\/SBIm\/SBI\/SBMT: vacina febre amarela em pacientes reum\u00e1ticos - 31\/01\/2018. [Portuguese]. 2018. Available from: \n                    https:\/\/sbim.org.br\/images\/files\/nt-fa-reumato-sbr-sbim-sbi-sbmt-180131.pdf\n                    \n                  . Accessed 2 July 2018."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1854-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:53:46Z","timestamp":1584060826000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1854-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1854-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"2 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee for studies with human subjects at Instituto Ren\u00e9 Rachou FIOCRUZ (CPqRR # 180911). All subjects gave written informed consent in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Two authors (MM and SL) are employees at the 17DD-YF vaccine manufacturer (Bio-Manguinhos, Funda\u00e7\u00e3o Oswaldo Cruz), and five authors work in other units of Funda\u00e7\u00e3o Oswaldo Cruz (ACC, VP, LA, ATC, and OM). Bias from competing interest was prevented by (1) collaboration of three clinical physicians (CF, AO, and LM) with experience in rheumatic diseases from Universidade de Bras\u00edlia, (2) one official member from the Brazilian Health Ministry (CD) with experience in vaccine epidemiological vigilance and policies, (3) two independent professionals working as undergraduate students (LF and IR), and (4) two post-doc researchers (JC and KT) working in the field of infectious diseases. The FIOCRUZ extramural coworkers contributed with the critical overview of the study design, volunteers\u2019 immunization and medical care, blood sample collection, blind sample handling and processing, data collection, statistical analysis, and data interpretation.The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"75"}}